Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.60 |
| ▸ | GSK3A | P49840 | 6/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | SCARB1 | Q8WTV0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1599651 | 0.90 | MAPK14 (0.73) | MAPK14GSK3AKDM4EALDH1A1MAPT | |
| SCHEMBL4948573 | 0.87 | MAPK14 (0.52) | MAPK14GSK3ASCARB1 | |
| SCHEMBL4949605 | 0.85 | MAPK14 (0.67) | MAPK14GSK3ASCARB1 | |
| SCHEMBL1600554 | 0.85 | MAPK14 (0.57) | MAPK14GSK3AKDM4EALDH1A1MAPT | |
| SCHEMBL1601023 | 0.85 | MAPK14 (0.58) | MAPK14GSK3AKDM4EALDH1A1MAPT | |
| SCHEMBL6165369 | 0.85 | MAPK14 (0.58) | MAPK14GSK3AKDM4EALDH1A1MAPT | |
| SCHEMBL4418875 | 0.84 | MAPK14 (0.59) | MAPK14GSK3AMAPK8KDM4EALDH1A1 | |
| SCHEMBL4944531 | 0.83 | MAPK14 (0.54) | MAPK14MAPK8KDM4EMAPTSCARB1 | |
| SCHEMBL1599955 | 0.81 | MAPK14 (0.62) | MAPK14SCARB1 | |
| SCHEMBL4413474 | 0.80 | MAPK14 (0.53) | MAPK14GSK3AKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089034-A2 | CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2008-07-24 | — | — | WO | disclosed |